Inflammatory Bowel Disease Treatment Market is expected to reach US$ 31.67 billion by 2031

Biologics Drug Class to Hold Largest Inflammatory Bowel Disease Treatment Market Share During 2023–2031 

According to our new research study on "Inflammatory Bowel Disease Treatment Market Size and Forecast (2021–2031), Global and Regional Share, Trend, and Growth Opportunity Analysis," the market value is projected to grow from US$ 24.05 billion in 2023 to US$ 31.67 billion by 2031; the market is anticipated to record a CAGR of 3.50% from 2023 to 2031. Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract. Crohn's disease and ulcerative colitis are the most common types of IBD. These conditions cause inflammation of the digestive tract lining, leading to symptoms such as abdominal pain, diarrhea, fatigue, and weight loss. IBD treatments focus on reducing inflammation, managing symptoms, and preventing complications through medication, lifestyle changes, and surgery (in some cases). Managing IBD typically requires ongoing medical care and monitoring to maintain remission and improve quality of life. Key factors driving the Inflammatory Bowel Disease Treatment Market growth include the rising prevalence of Crohn's disease and ulcerative colitis, and the rising number of product launches. Technological advancements are likely to bring new Inflammatory Bowel Disease Treatment Market trends in the coming years. The development of innovative treatments through continuous research and favorable initiatives by governments are expected to fuel the Inflammatory Bowel Disease Treatment Market growth.

An upsurge in the geriatric population is a significant catalyst for the Inflammatory Bowel Disease Treatment Market. As individuals grow older, their susceptibility to gastrointestinal disorders tends to rise due to physiological changes and weakened immune systems, along with the cumulative effects of lifestyle factors. Consequently, the demand for effective IBD therapies is on the rise to address the unique needs and complexities of elderly patients. Moreover, healthcare systems realize the importance of tailored treatment approaches that consider factors such as comorbidities, medication interactions, and diminished organ function, which are common in older adults. Thus, pharmaceutical companies and research institutions are increasingly focusing on developing therapies specifically tailored to the geriatric population, taking into account factors such as drug metabolism, dosing adjustments, and safety profiles. Healthcare providers are also investing in multidisciplinary care models and specialized geriatric clinics to optimize disease management and enhance the quality of life for elderly individuals living with IBD. Therefore, the increasing geriatric population bolsters the Inflammatory Bowel Disease Treatment Market size.

Inflammatory Bowel Disease Treatment Market, by Region, 2023 (%)

Source: The Insight Partners Analysis

The Inflammatory Bowel Disease Treatment Market is anticipated to develop over the forecast period owing to the increasing number of product launches, contributing to the development of robust product pipelines. ABBV-154 from AbbVie is an anti-TNF GRM ADC that is presently undergoing phase II clinical studies and is anticipated to go on sale in the upcoming years. Similarly, Lilly's mirikizumab, a big molecule that may be studied for treating IBD, is anticipated to hit the market in 2023. The currently available treatments focus on unlocking benefits such as long-term remission, lower risk of sequelae, and decreased inflammation. In addition, hospitals and other healthcare facilities collaborate closely with pharmaceutical companies to carry out clinical trials and guarantee patient safety.

The Inflammatory Bowel Disease Treatment Market forecast can help stakeholders in this marketplace plan their growth strategies. Mindray Medical International Limited; AbbVie Inc; Takeda Pharmaceutical Company Limited; Pfizer Inc; Biogen; Novartis AG; Lilly; UCB S.A.; CELLTRION INC.; Merck & Co., Inc.; and Johnson & Johnson Services, Inc. are a few key companies profiled in the Inflammatory Bowel Disease Treatment Market report. Companies have been implementing organic (product launches, expansions, and product approvals) and inorganic (partnerships and collaborations) strategies that contribute to their growth and lead to market progress.

The Inflammatory Bowel Disease Treatment Market analysis has been carried out by considering the following segments: drug class, disease indication, and distribution channel. The geographic scope of the Inflammatory Bowel Disease Treatment Market report includes North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). In 2023, North America held the largest Inflammatory Bowel Disease Treatment Market share. The US holds the largest market share in North America. The rising incidence of IBD in the US, the growing need for early diagnosis, and the introduction of new products by major industry players are among the factors contributing to the market expansion.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com